The Horizon Health 2025 programme aims to accelerate early-stage clinical research for promising health innovations and to support the development of new therapeutic approaches across Europe. 

“We are extremely pleased with the funding we have received from this highly competitive program. Independent experts assessed our project as being of exceptionally high quality, which is a significant recognition of our long-term efforts in developing boron carriers for Boron Neutron Capture Therapy. Our mission is to help build a European BNCT ecosystem, and both our consortium and clinical development plan strongly support this goal. We believe BNCT will offer new treatment options for several hard-to-treat cancers in the future,” says Juha Jouhki, Chief Executive Officer of Tenboron.

Tenboron has assembled a strong international consortium for the project, including the BNCT research group led by Professor Ignacio Porras from the University of Granada (Spain), and The Swallows, a UK-based patient organization for head and neck cancer. The funding will be used for Phase 1 and 2 BNCT studies of the TB0010 boron carrier in patients with recurrent head and neck cancer, as well as preparatory activities for the studies. The aim is to evaluate the clinical efficacy and safety of the TB0010-BNCT in patients. Patients will receive neutron irradiation in addition to the TB0010 carrier, enabling for the first time evaluation of the therapeutic benefit of BNCT using this carrier.